EMEA-000611-PIP01-09 - paediatric investigation plan

Pegaptanib sodium

Key facts

• Invented name:
  • Macugen
  • Macugen
• Active Substance:
  Pegaptanib sodium
• Therapeutic area:
  Ophthalmology
• Decision number:
  P/195/2009
• PIP number:
  EMEA-000611-PIP01-09
• Pharmaceutical form(s):
  Solution for injection
• Condition(s) / indication(s):
  Diabetic retinopathy
• Route(s) of administration:
  Intravitreal use
• Contact for public enquiries:

  Pfizer Global Research & Development

  E-mail: [e-mail]; Country: United Kingdom; Phone: [phone]; Fax: [phone]

• Decision type:
  W: decision granting a waiver in all age groups for all conditions or indications
• Decision date:
  07/10/2009

Decision

P/195/2009: European Medicines Agency decision of 7 October 2009 on the granting of a product specific waiver for pegaptanib sodium, Macugen (EMEA-000611-PIP01-09) in accordance with Regulation (EC) No 1901/2006 of the E...

AdoptedReference Number: EMEA/604653/2009